Loading
institutionsInstitution
Dartmouth Cancer Center
Dartmouth Cancer Center serves rural northern New England as an NCI comprehensive centre; its immunologists founded Medarex, whose human antibody platform produced ipilimumab and nivolumab, and the Dartmouth Institute's work on overdiagnosis has shaped the cancer screening debate.
Also called: Norris Cotton Cancer Center
Overview
NCI-designated since 1978 and comprehensive since 1990, Dartmouth Cancer Center (renamed from Norris Cotton in 2022) serves northern New England from Dartmouth-Hitchcock Medical Center. Medarex, the company whose fully human antibody platform produced ipilimumab and nivolumab before Bristol Myers Squibb acquired it in 2009, was founded in 1987 by Dartmouth immunologists. The Dartmouth Institute's health-policy research, including Gilbert Welch's work on overdiagnosis, has shaped debate on cancer screening. Current research programmes cover immunology and cancer immunotherapy, cancer biology, and rural cancer control.
Location
Lebanon, NH, US
Type
cancer center · Dartmouth College
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#97 · 39 points (0 Newsweek + 15 NCI + 24 from 12 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Dartmouth Cancer Center, including child institutions. 220 works · 2,562 citations · 75% open access · 11% clinical trials · 1% reviews.
Oncology works per year
382022
632023
482024
462025
252026
Most works
- Anna N.A. Tosteson28 works
- Gabriel A. Brooks27 works
- Razelle Kurzrock23 works
- Hirotaka Miyashita23 works
- Paul DePietro19 works
- Sarabjot Pabla19 works
- Shumei Kato19 works
- Daisuke Nishizaki17 works
- Jeffrey M. Conroy17 works
- Konstantin H. Dragnev17 works
Most cited
- Cancer immunology
- Overdiagnosis and screening policy
- Rural cancer care
Similar pages
- PersonMichael A. Postow
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1.
- TrialCheckMate 9DW
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1.
- PersonPaul Baas
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1.
- TrialA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Shares Ipilimumab, Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
- PersonF. Stephen Hodi
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1.
- TrialKEYNOTE-006
Shares CTLA-4, Ipilimumab, PD-1, Melanoma.
- TrialCheckMate 648
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1.
- TrialA Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed
Shares Bristol Myers Squibb, Nivolumab, Melanoma, Immune checkpoint inhibitors.
cancers
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-CTLA-4)
Ipilimumab · Yervoy
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)